# Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children

> **NCT01323946** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 113 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK Biologicals' investigational vaccine GSK1562902A

## Key facts

- **NCT ID:** NCT01323946
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-18
- **Primary completion:** 2012-06-22
- **Final completion:** 2012-11-02
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2019-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323946, "Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01323946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*